Literature DB >> 2525524

Antihypertensive effect of a 5-day infusion of atrial natriuretic factor in humans.

W M Janssen1, D de Zeeuw, G K van der Hem, P E de Jong.   

Abstract

Atrial natriuretic factor was infused in a low dose (0.2 microgram/min) during 5 days in six patients with essential hypertension. Atrial natriuretic factor infusion caused plasma levels of atrial natriuretic factor to increase from 49 +/- 10 to 106 +/- 19 pg/ml. Within 4 hours after the start of the atrial natriuretic factor infusion, urinary sodium excretion increased in all subjects. Sodium balance was regained after 24 hours with a net loss of 72.3 +/- 14.6 mmol. However, systolic as well as diastolic blood pressure started to decrease gradually in all subjects only after 12 hours of atrial natriuretic factor infusion, reaching a stable level after 36 hours with a decrease of 11.5 +/- 1.5% and 10.3 +/- 0.8%, respectively. Heart rate increased in parallel by 12.6 +/- 3.1%. Hematocrit rose 7.1 +/- 2.3%. After cessation of atrial natriuretic factor infusion, plasma atrial natriuretic factor levels, sodium balance, and hematocrit returned to baseline within 24 hours, whereas blood pressure slowly returned toward baseline values over 3 days. These data show that chronic atrial natriuretic factor infusion in patients with essential hypertension causes a negative sodium balance and a rise in hematocrit, followed by a smooth decrease in blood pressure with a rise in heart rate until a new equilibrium is reached after approximately 2 days. Thus, atrial natriuretic factor in low doses appears intimately involved in the regulation of sodium balance and blood pressure in humans. Moreover, these data suggest that atrial natriuretic factor-like substances will eventually become useful antihypertensive drugs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2525524     DOI: 10.1161/01.hyp.13.6.640

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  15 in total

1.  Plasma insulin during physiological and pathophysiological changes in atrial natriuretic factor.

Authors:  P Ferrari; S Shaw; W Riesen; P Weidmann
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Therapeutic use of atrial natriuretic factor.

Authors:  J M Connell; A G Jardine; D B Northridge
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

3.  Institute for Quality in Laboratory Medicine series--controversies in laboratory medicine: insights into B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide measurements.

Authors:  Robert H Christenson; W H Wilson Tang
Journal:  MedGenMed       Date:  2006-05-31

Review 4.  The renin-angiotensin-aldosterone system and the cardiac natriuretic peptides.

Authors:  A M Richards
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 5.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

6.  A gene therapy approach for long-term normalization of blood pressure in hypertensive mice by ANP-secreting human skin grafts.

Authors:  Jean-Philippe Therrien; Soo Mi Kim; Atsushi Terunuma; Yan Qin; Christine L Tock; Wolfgang Pfützner; Manabu Ohyama; Jurgen Schnermann; Jonathan C Vogel
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-11       Impact factor: 11.205

7.  Pharmacokinetic-pharmacodynamic (PK-PD) modeling for a new antihypertensive agent (neutral metalloendopeptidase inhibitor SCH 42354) in patients with mild to moderate hypertension.

Authors:  S H Fettner; S Pai; G R Zhu; T Kosoglou; C R Banfield; V Batra
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 8.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

Review 9.  Vasopeptidase inhibitors: will they have a role in clinical practice?

Authors:  Matthew I Worthley; Roberto Corti; Stephen G Worthley
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

Review 10.  B-type natriuretic peptide: physiologic role and assay characteristics.

Authors:  Hassan M E Azzazy; Robert H Christenson
Journal:  Heart Fail Rev       Date:  2003-10       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.